These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32853525)

  • 21. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
    Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF
    Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (M
    Rao P; Shukla A; Parmar P; Rawal RM; Patel B; Saraf M; Goswami D
    Biophys Chem; 2020 Sep; 264():106425. PubMed ID: 32663708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes.
    Kandeel M; Ibrahim A; Fayez M; Al-Nazawi M
    J Med Virol; 2020 Jun; 92(6):660-666. PubMed ID: 32159237
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
    OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study.
    Wang J
    J Chem Inf Model; 2020 Jun; 60(6):3277-3286. PubMed ID: 32315171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection.
    Hattori SI; Higshi-Kuwata N; Raghavaiah J; Das D; Bulut H; Davis DA; Takamatsu Y; Matsuda K; Takamune N; Kishimoto N; Okamura T; Misumi S; Yarchoan R; Maeda K; Ghosh AK; Mitsuya H
    mBio; 2020 Aug; 11(4):. PubMed ID: 32820005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel
    Sencanski M; Perovic V; Pajovic SB; Adzic M; Paessler S; Glisic S
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32842509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors.
    Achutha AS; Pushpa VL; Suchitra S
    J Proteome Res; 2020 Nov; 19(11):4706-4717. PubMed ID: 32960061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors.
    He J; Hu L; Huang X; Wang C; Zhang Z; Wang Y; Zhang D; Ye W
    Int J Antimicrob Agents; 2020 Aug; 56(2):106055. PubMed ID: 32534187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL
    Chen YW; Yiu CB; Wong KY
    F1000Res; 2020; 9():129. PubMed ID: 32194944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.
    Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T
    Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening.
    Abian O; Ortega-Alarcon D; Jimenez-Alesanco A; Ceballos-Laita L; Vega S; Reyburn HT; Rizzuti B; Velazquez-Campoy A
    Int J Biol Macromol; 2020 Dec; 164():1693-1703. PubMed ID: 32745548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemical and Computational Approach of Selected Phytocompounds from
    Rakib A; Paul A; Chy MNU; Sami SA; Baral SK; Majumder M; Tareq AM; Amin MN; Shahriar A; Uddin MZ; Dutta M; Tallei TE; Emran TB; Simal-Gandara J
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32872217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-based lead optimization of herbal medicine rutin for inhibiting SARS-CoV-2's main protease.
    Huynh T; Wang H; Luan B
    Phys Chem Chem Phys; 2020 Nov; 22(43):25335-25343. PubMed ID: 33140777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protease Inhibitory Effect of Natural Polyphenolic Compounds on SARS-CoV-2: An In Silico Study.
    Singh R; Gautam A; Chandel S; Ghosh A; Dey D; Roy S; Ravichandiran V; Ghosh D
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33050360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV and SARS-CoV-2 main protease residue interaction networks change when bound to inhibitor N3.
    Griffin JWD
    J Struct Biol; 2020 Sep; 211(3):107575. PubMed ID: 32653646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative genome analysis of novel coronavirus (SARS-CoV-2) from different geographical locations and the effect of mutations on major target proteins: An in silico insight.
    Khan MI; Khan ZA; Baig MH; Ahmad I; Farouk AE; Song YG; Dong JJ
    PLoS One; 2020; 15(9):e0238344. PubMed ID: 32881907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
    Fu L; Ye F; Feng Y; Yu F; Wang Q; Wu Y; Zhao C; Sun H; Huang B; Niu P; Song H; Shi Y; Li X; Tan W; Qi J; Gao GF
    Nat Commun; 2020 Sep; 11(1):4417. PubMed ID: 32887884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.